December 15, 2016 / 9:49 AM / 7 months ago

BRIEF-Galapagos reports publication of Phase 2 study with filgotinib in Crohn's disease in The Lancet

1 Min Read

Dec 15 (Reuters) - Galapagos NV :

* "FITZROY was the first double-blind, placebo-controlled study to use centrally read endoscopies to ensure the selective recruitment of patients with active disease including mucosal ulceration" - Dr Vermeire

* An increase in hemoglobin was also observed in FITZROY, without difference between filgotinib and placebo. No clinically significant changes from baseline in neutrophils or liver function tests were observed

* "Phase 3 trials with the compound are underway" - Dr Vermeire

* Filgotinib is an investigational drug and its efficacy and safety have not been established

* Overall, in the FITZROY study at 20 weeks of treatment, filgotinib demonstrated a favorable safety profile consistent with the previous darwin STUDIES in RA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below